SKVI SKINVISIBLE, INC.
Pharmaceutical Preparations · OTC · SEC CIK 1085277 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY5.8%
TTM net income YoY-111.2%
TTM EPS YoY—
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR—
Margins
Gross margin100.0%
Operating margin-2,193.7%
Net margin-4,898.2%
FCF margin—
EBITDA margin-2,097.8%
Returns
ROE—
ROA-829.6%
ROIC (approx.)—
Asset turnover0.17x
Leverage & solvency
Liabilities / assets9,592.8%
Debt / equity—
Current ratio0.01x
Interest coverage-0.81x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-759.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $20,000 | $20,000 |
| Gross profit | $20,000 | $20,000 |
| SG&A expense | $496,076 | $589,151 |
| Operating income | -$496,315 | -$589,589 |
| Interest expense | $572,249 | $669,438 |
| Net income | -$1.06M | -$565,654 |
| EBITDA | -$476,076 | -$569,151 |
| EPS (diluted) | — | -0.11 |
| Weighted avg. shares (diluted) | — | 5.06M |
| Balance sheet | ||
| Cash & equivalents | $2,620 | $10,336 |
| Receivables | $5,000 | $5,000 |
| Current assets | $27,531 | $42,028 |
| Intangibles | $100,036 | $116,189 |
| Total assets | $127,567 | $158,217 |
| Current liabilities | $5.02M | $3.66M |
| Total liabilities | $10.39M | $9.38M |
| Shareholders' equity | -$10.26M | -$9.22M |
| Shares outstanding | 5.40M | 5.32M |
| Cash flow statement | ||
| Operating cash flow | -$38,410 | -$69,834 |
| Capital expenditure | $4,086 | $9,218 |
| Free cash flow | -$42,496 | -$79,052 |
| Investing cash flow | -$4,086 | -$9,218 |
| Financing cash flow | $34,780 | $88,500 |
| Depreciation & amortization | $20,239 | $20,438 |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.